RAMSAY DAVID A 4

What Happened

• David A. Ramsay, Interim Chief Financial Officer of Halozyme Therapeutics, was granted a derivative award of 10,000 shares on 2026-04-01. The award shows an acquisition price of $0.00 (no cash paid). The award is subject to vesting and a post-vesting holding period.

Key Details

• Transaction date: 2026-04-01; transaction type: Award/Grant (code A).
• Number of shares: 10,000; price per share reported: $0.00; reported value: $0.
• Vesting and restrictions: This award vests in full on June 30, 2026 only if the reporting person remains employed through that date, and is subject to a one-year holding period after vesting (see footnote F1).
• Shares owned after transaction: Not specified in this Form 4 filing.
• Filing timeliness: Filed 2026-04-02 for a 2026-04-01 grant — no late filing indicated.

Context

• This is a time-based equity award (derivative grant) rather than an open-market purchase or sale; it does not reflect an immediate cash investment or liquidity event. Retail investors should view such awards as a standard element of executive compensation tied to continued employment and retention rather than a direct buy/sell signal.